AG˹ٷ

STOCK TITAN

[Form 4] REGENXBIO Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

REGENXBIO Inc. (RGNX) � Form 4 Insider Transaction

Chief Executive Officer and Director Curran Simpson reported a Code F transaction on 07/01/2025 involving 4,701 shares of RGNX common stock. Code F indicates shares were withheld by the company to satisfy tax obligations upon the vesting of previously granted restricted stock units (RSUs) dated 07/01/2024. The shares were valued at $8.23, the closing price on the vesting date.

Following the withholding, Simpson’s direct beneficial ownership stands at 252,331 common shares. No open-market purchase or sale occurred, and no derivative securities were exercised or disposed of.

  • Transaction type: tax-related share withholding (non-cash).
  • Remaining ownership suggests continued alignment with shareholders.
  • No new options, warrants, or other derivatives reported.

The filing is routine and carries limited market impact, primarily confirming the executive’s updated share count.

REGENXBIO Inc. (RGNX) � Transazione interna Form 4

Il CEO e Direttore Curran Simpson ha comunicato una transazione di Codice F il 01/07/2025 riguardante 4.701 azioni ordinarie di RGNX. Il Codice F indica che le azioni sono state trattenute dalla società per soddisfare obblighi fiscali al momento della maturazione di unità azionarie vincolate (RSU) precedentemente assegnate il 01/07/2024. Le azioni sono state valutate a 8,23 $, il prezzo di chiusura alla data di maturazione.

Dopo la trattenuta, la proprietà diretta di Simpson ammonta a 252.331 azioni ordinarie. Non si sono verificati acquisti o vendite sul mercato aperto, né esercizi o dismissioni di strumenti derivati.

  • Tipo di transazione: trattenuta azioni per obblighi fiscali (non in contanti).
  • La proprietà residua indica un continuo allineamento con gli azionisti.
  • Non sono stati segnalati nuovi opzioni, warrant o altri derivati.

La comunicazione è di routine e ha un impatto limitato sul mercato, confermando principalmente l’aggiornamento del numero di azioni detenute dall’esecutivo.

REGENXBIO Inc. (RGNX) � Transacción interna Formulario 4

El Director Ejecutivo y Director Curran Simpson reportó una transacción de Código F el 01/07/2025 que involucra 4.701 acciones ordinarias de RGNX. El Código F indica que las acciones fueron retenidas por la compañía para cumplir con obligaciones fiscales al consolidarse unidades restringidas de acciones (RSU) otorgadas previamente el 01/07/2024. Las acciones se valoraron en $8.23, el precio de cierre en la fecha de consolidación.

Tras la retención, la propiedad directa de Simpson es de 252.331 acciones ordinarias. No hubo compras ni ventas en el mercado abierto, ni se ejercieron o dispusieron valores derivados.

  • Tipo de transacción: retención de acciones por impuestos (no en efectivo).
  • La propiedad restante sugiere una alineación continua con los accionistas.
  • No se reportaron nuevas opciones, warrants u otros derivados.

La presentación es rutinaria y tiene un impacto limitado en el mercado, confirmando principalmente el recuento actualizado de acciones del ejecutivo.

REGENXBIO Inc. (RGNX) � Form 4 내부� 거래 보고

최고경영� � 이사� 커런 심슨은 2025� 7� 1� 코드 F 거래� 보고했으�, 이는 RGNX 보통� 4,701�와 관련됩니다. 코드 F� 2024� 7� 1일에 부여된 제한 주식 단위(RSU)� 권리 확정 � 세금 의무� 충족하기 위해 회사가 주식� 원천징수했음� 의미합니�. 해당 주식은 권리 확정� 종가� 8.23달러� 평가되었습니�.

원천징수 � 심슨� 직접적인 실질 소유 주식 수는 252,331�입니�. 공개 시장에서� 매매� 파생상품 행사� 없었습니�.

  • 거래 유형: 세금 관� 주식 원천징수(비현금성).
  • 남은 소유 주식은 주주와� 지속적� 이해관� 일치� 나타냅니�.
  • 새로� 옵션, 워런� 또는 기타 파생상품 보고 없음.

이번 보고� 일상적인 절차� 시장� 미치� 영향은 제한적이�, 주로 경영진의 최신 주식 보유 현황� 확인하는 내용입니�.

REGENXBIO Inc. (RGNX) � Transaction d’initié Formulaire 4

Le PDG et administrateur Curran Simpson a déclaré une transaction de Code F le 01/07/2025 portant sur 4 701 actions ordinaires de RGNX. Le Code F indique que des actions ont été retenues par la société pour satisfaire des obligations fiscales lors de l’acquisition de Restricted Stock Units (RSU) précédemment attribuées le 01/07/2024. Les actions ont été valorisées à 8,23 $, le cours de clôture à la date d’acquisition.

Après cette retenue, la détention directe de Simpson s’élève à 252 331 actions ordinaires. Aucune transaction sur le marché ouvert ni exercice ou cession de produits dérivés n’a eu lieu.

  • Type de transaction : retenue d’actions liée à l’impôt (non monétaire).
  • La détention restante suggère une continuité d’alignement avec les actionnaires.
  • Aucune nouvelle option, warrant ou autre dérivé signalé.

Le dépôt est de routine et a un impact limité sur le marché, confirmant principalement le nombre actualisé d’actions détenues par le dirigeant.

REGENXBIO Inc. (RGNX) � Insider-Transaktion Form 4

Geschäftsführer und Direktor Curran Simpson meldete am 01.07.2025 eine Code F-Transaktion, bei der 4.701 Aktien der RGNX-Stammaktien betroffen waren. Code F bedeutet, dass Aktien vom Unternehmen einbehalten wurden, um Steuerverpflichtungen bei der Vesting von zuvor gewährten Restricted Stock Units (RSUs) vom 01.07.2024 zu erfüllen. Die Aktien wurden zum Schlusskurs von 8,23 $ am Vesting-Tag bewertet.

Nach der Einbehaltung beträgt Simpsons direkte wirtschaftliche Beteiligung 252.331 Stammaktien. Es gab keine Käufe oder Verkäufe am offenen Markt und keine Ausübung oder Veräußerung von Derivaten.

  • Transaktionstyp: steuerbedingtes Aktieneinbehalt (nicht in bar).
  • Verbleibende Beteiligung zeigt weiterhin Ausrichtung mit den Aktionären.
  • Keine neuen Optionen, Warrants oder andere Derivate gemeldet.

Die Meldung ist routinemäßig und hat nur begrenzte Auswirkungen auf den Markt, bestätigt hauptsächlich die aktualisierte Aktienanzahl des Geschäftsführers.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding; neutral impact

The Form 4 shows a standard Code F transaction where REGENXBIO withheld 4,701 shares from CEO Curran Simpson to cover payroll taxes on RSU vesting. Such non-discretionary transactions neither signal bullish nor bearish sentiment. Post-transaction holdings of 252,331 shares demonstrate a sizable ongoing stake, maintaining governance alignment but offering no new insight into future company performance.

REGENXBIO Inc. (RGNX) � Transazione interna Form 4

Il CEO e Direttore Curran Simpson ha comunicato una transazione di Codice F il 01/07/2025 riguardante 4.701 azioni ordinarie di RGNX. Il Codice F indica che le azioni sono state trattenute dalla società per soddisfare obblighi fiscali al momento della maturazione di unità azionarie vincolate (RSU) precedentemente assegnate il 01/07/2024. Le azioni sono state valutate a 8,23 $, il prezzo di chiusura alla data di maturazione.

Dopo la trattenuta, la proprietà diretta di Simpson ammonta a 252.331 azioni ordinarie. Non si sono verificati acquisti o vendite sul mercato aperto, né esercizi o dismissioni di strumenti derivati.

  • Tipo di transazione: trattenuta azioni per obblighi fiscali (non in contanti).
  • La proprietà residua indica un continuo allineamento con gli azionisti.
  • Non sono stati segnalati nuovi opzioni, warrant o altri derivati.

La comunicazione è di routine e ha un impatto limitato sul mercato, confermando principalmente l’aggiornamento del numero di azioni detenute dall’esecutivo.

REGENXBIO Inc. (RGNX) � Transacción interna Formulario 4

El Director Ejecutivo y Director Curran Simpson reportó una transacción de Código F el 01/07/2025 que involucra 4.701 acciones ordinarias de RGNX. El Código F indica que las acciones fueron retenidas por la compañía para cumplir con obligaciones fiscales al consolidarse unidades restringidas de acciones (RSU) otorgadas previamente el 01/07/2024. Las acciones se valoraron en $8.23, el precio de cierre en la fecha de consolidación.

Tras la retención, la propiedad directa de Simpson es de 252.331 acciones ordinarias. No hubo compras ni ventas en el mercado abierto, ni se ejercieron o dispusieron valores derivados.

  • Tipo de transacción: retención de acciones por impuestos (no en efectivo).
  • La propiedad restante sugiere una alineación continua con los accionistas.
  • No se reportaron nuevas opciones, warrants u otros derivados.

La presentación es rutinaria y tiene un impacto limitado en el mercado, confirmando principalmente el recuento actualizado de acciones del ejecutivo.

REGENXBIO Inc. (RGNX) � Form 4 내부� 거래 보고

최고경영� � 이사� 커런 심슨은 2025� 7� 1� 코드 F 거래� 보고했으�, 이는 RGNX 보통� 4,701�와 관련됩니다. 코드 F� 2024� 7� 1일에 부여된 제한 주식 단위(RSU)� 권리 확정 � 세금 의무� 충족하기 위해 회사가 주식� 원천징수했음� 의미합니�. 해당 주식은 권리 확정� 종가� 8.23달러� 평가되었습니�.

원천징수 � 심슨� 직접적인 실질 소유 주식 수는 252,331�입니�. 공개 시장에서� 매매� 파생상품 행사� 없었습니�.

  • 거래 유형: 세금 관� 주식 원천징수(비현금성).
  • 남은 소유 주식은 주주와� 지속적� 이해관� 일치� 나타냅니�.
  • 새로� 옵션, 워런� 또는 기타 파생상품 보고 없음.

이번 보고� 일상적인 절차� 시장� 미치� 영향은 제한적이�, 주로 경영진의 최신 주식 보유 현황� 확인하는 내용입니�.

REGENXBIO Inc. (RGNX) � Transaction d’initié Formulaire 4

Le PDG et administrateur Curran Simpson a déclaré une transaction de Code F le 01/07/2025 portant sur 4 701 actions ordinaires de RGNX. Le Code F indique que des actions ont été retenues par la société pour satisfaire des obligations fiscales lors de l’acquisition de Restricted Stock Units (RSU) précédemment attribuées le 01/07/2024. Les actions ont été valorisées à 8,23 $, le cours de clôture à la date d’acquisition.

Après cette retenue, la détention directe de Simpson s’élève à 252 331 actions ordinaires. Aucune transaction sur le marché ouvert ni exercice ou cession de produits dérivés n’a eu lieu.

  • Type de transaction : retenue d’actions liée à l’impôt (non monétaire).
  • La détention restante suggère une continuité d’alignement avec les actionnaires.
  • Aucune nouvelle option, warrant ou autre dérivé signalé.

Le dépôt est de routine et a un impact limité sur le marché, confirmant principalement le nombre actualisé d’actions détenues par le dirigeant.

REGENXBIO Inc. (RGNX) � Insider-Transaktion Form 4

Geschäftsführer und Direktor Curran Simpson meldete am 01.07.2025 eine Code F-Transaktion, bei der 4.701 Aktien der RGNX-Stammaktien betroffen waren. Code F bedeutet, dass Aktien vom Unternehmen einbehalten wurden, um Steuerverpflichtungen bei der Vesting von zuvor gewährten Restricted Stock Units (RSUs) vom 01.07.2024 zu erfüllen. Die Aktien wurden zum Schlusskurs von 8,23 $ am Vesting-Tag bewertet.

Nach der Einbehaltung beträgt Simpsons direkte wirtschaftliche Beteiligung 252.331 Stammaktien. Es gab keine Käufe oder Verkäufe am offenen Markt und keine Ausübung oder Veräußerung von Derivaten.

  • Transaktionstyp: steuerbedingtes Aktieneinbehalt (nicht in bar).
  • Verbleibende Beteiligung zeigt weiterhin Ausrichtung mit den Aktionären.
  • Keine neuen Optionen, Warrants oder andere Derivate gemeldet.

Die Meldung ist routinemäßig und hat nur begrenzte Auswirkungen auf den Markt, bestätigt hauptsächlich die aktualisierte Aktienanzahl des Geschäftsführers.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Simpson Curran

(Last) (First) (Middle)
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 F 4,701(1) D $8.23 252,331 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2025.
Remarks:
/s/ Patrick J. Christmas as attorney-in-fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of insider transaction did REGENXBIO (RGNX) report?

It was a Code F transaction—shares withheld to cover taxes on vested RSUs, not an open-market trade.

How many REGENXBIO shares were withheld for taxes?

4,701 common shares were withheld.

What is the CEO’s remaining direct ownership after the transaction?

Curran Simpson now directly owns 252,331 shares of RGNX common stock.

Was the transaction a sale or purchase on the open market?

No. Code F indicates a non-open-market, non-discretionary tax-withholding event.

At what price were the shares valued for withholding?

The shares were valued at $8.23, the issuer’s closing price on 07/01/2025.
Regenxbio

NASDAQ:RGNX

RGNX Rankings

RGNX Latest News

RGNX Latest SEC Filings

RGNX Stock Data

434.35M
46.49M
7.31%
87.5%
12.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
ROCKVILLE